192 related articles for article (PubMed ID: 28284212)
1. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
[TBL] [Abstract][Full Text] [Related]
2. Specific Features of Fibrotic Lung Fibroblasts Highly Sensitive to Fibrotic Processes Mediated via TGF-β-ERK5 Interaction.
Kadoya K; Togo S; Tulafu M; Namba Y; Iwai M; Watanabe J; Okabe T; Jin J; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Takeda T; Kondo N; Takahashi K
Cell Physiol Biochem; 2019; 52(4):822-837. PubMed ID: 30946557
[TBL] [Abstract][Full Text] [Related]
3. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
4. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
6. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
7. ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation.
Kim S; Lim JH; Woo CH
Am J Pathol; 2013 Dec; 183(6):1758-1768. PubMed ID: 24095924
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
Rodrigo GJ; Plaza V
Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
[TBL] [Abstract][Full Text] [Related]
9. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
[TBL] [Abstract][Full Text] [Related]
10. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
13. Effects of (a Combination of) the Beta
Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
Cells; 2021 May; 10(5):. PubMed ID: 34069899
[TBL] [Abstract][Full Text] [Related]
14. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Schachter EN
Drugs Today (Barc); 2013 Jul; 49(7):437-46. PubMed ID: 23914352
[TBL] [Abstract][Full Text] [Related]
15. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist T; Fitting JW; Schmidt U; Geiser T; Wild C; Kostikas K; Clemens A; Brutsche M
Respir Res; 2017 Jan; 18(1):13. PubMed ID: 28077140
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
[TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
19. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
